Compare Stocks: MDWD, SGMT, AURA, and NGNE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$6.00	$7.24	$4.73 ▼ $9.53	$622.26M	0.4	862,961 shs	1.12 million shs
MDWD MediWound	$13.84	$13.66	$12.52 ▼ $20.03	$177.84M	0.14	100,494 shs	72,571 shs
NGNE Neurogene	$28.31	$35.71	$15.93 ▼ $43.66	$566.48M	1.69	314,184 shs	200,066 shs
SGMT Sagimet Biosciences	$9.24	$9.58	$4.50 ▼ $11.45	$574.36M	3.45	1.09 million shs	1.25 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	0.00%	-6.83%	-18.92%	-12.79%	-2.60%
MDWD MediWound	0.00%	+3.28%	+9.32%	-8.22%	-22.64%
NGNE Neurogene	0.00%	-11.78%	-22.61%	-12.30%	+58.87%
SGMT Sagimet Biosciences	0.00%	-16.68%	-12.42%	+18.61%	+25.89%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$6.00	$7.24	$4.73 ▼ $9.53	$622.26M	0.4	862,961 shs	1.12 million shs
MDWD MediWound	$13.84	$13.66	$12.52 ▼ $20.03	$177.84M	0.14	100,494 shs	72,571 shs
NGNE Neurogene	$28.31	$35.71	$15.93 ▼ $43.66	$566.48M	1.69	314,184 shs	200,066 shs
SGMT Sagimet Biosciences	$9.24	$9.58	$4.50 ▼ $11.45	$574.36M	3.45	1.09 million shs	1.25 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	0.00%	-6.83%	-18.92%	-12.79%	-2.60%
MDWD MediWound	0.00%	+3.28%	+9.32%	-8.22%	-22.64%
NGNE Neurogene	0.00%	-11.78%	-22.61%	-12.30%	+58.87%
SGMT Sagimet Biosciences	0.00%	-16.68%	-12.42%	+18.61%	+25.89%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AURA Aura Biosciences	2.33	Hold	$17.50	191.67% Upside
MDWD MediWound	2.50	Moderate Buy	$33.00	138.44% Upside
NGNE Neurogene	2.83	Moderate Buy	$83.67	195.54% Upside
SGMT Sagimet Biosciences	2.58	Moderate Buy	$25.34	174.23% Upside

Current Analyst Ratings Breakdown

Latest MDWD, SGMT, AURA, and NGNE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	MDWD MediWound	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/24/2026	SGMT Sagimet Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell	$7.00
9/24/2026	SGMT Sagimet Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell	$7.00
9/16/2026	MDWD MediWound	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/9/2026	SGMT Sagimet Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$10.71
9/9/2026	SGMT Sagimet Biosciences	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$8.00 ➝ $18.00
9/9/2026	SGMT Sagimet Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$10.71
9/8/2026	MDWD MediWound	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/25/2026	SGMT Sagimet Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$29.00
8/14/2026	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$32.00 ➝ $30.00
8/14/2026	SGMT Sagimet Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$2.16 per share	N/A
MDWD MediWound	$16.96M	10.49	N/A	N/A	$3.40 per share	4.07
NGNE Neurogene	$930K	609.12	N/A	N/A	$17.10 per share	1.66
SGMT Sagimet Biosciences	$2M	287.18	N/A	N/A	$3.42 per share	2.70

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AURA Aura Biosciences	-$106.19M	-$1.75	N/A	N/A	N/A	N/A	-73.18%	-62.00%	11/12/2026 (Estimated)
MDWD MediWound	-$23.88M	-$1.80	N/A	N/A	N/A	-170.10%	-47.24%	-24.27%	11/19/2026 (Estimated)
NGNE Neurogene	-$90.35M	-$5.03	N/A	N/A	N/A	N/A	-45.10%	-41.00%	11/12/2026 (Estimated)
SGMT Sagimet Biosciences	-$51.04M	-$1.28	N/A	N/A	N/A	N/A	-31.96%	-30.57%	11/12/2026 (Estimated)

Latest MDWD, SGMT, AURA, and NGNE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	MDWD MediWound	-$0.7617	-$0.77	-$0.0083	-$0.77	$2.59 million	$3.09 million
8/11/2026	Q2 2026	AURA Aura Biosciences	-$0.3750	-$0.48	-$0.1050	-$0.48	N/A	N/A
8/11/2026	Q2 2026	NGNE Neurogene	-$1.42	-$1.53	-$0.11	-$1.53	N/A	N/A
8/11/2026	Q2 2026	SGMT Sagimet Biosciences	-$0.2510	-$0.26	-$0.0090	-$0.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A
NGNE Neurogene	N/A	N/A	N/A	N/A	N/A
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AURA Aura Biosciences	N/A	16.82	16.82
MDWD MediWound	N/A	2.32	2.09
NGNE Neurogene	N/A	10.65	10.64
SGMT Sagimet Biosciences	N/A	45.03	45.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AURA Aura Biosciences	96.75%
MDWD MediWound	46.83%
NGNE Neurogene	52.37%
SGMT Sagimet Biosciences	87.86%

Insider Ownership

Company	Insider Ownership
AURA Aura Biosciences	1.90%
MDWD MediWound	9.20%
NGNE Neurogene	11.68%
SGMT Sagimet Biosciences	11.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AURA Aura Biosciences	113	103.71 million	101.74 million	Not Optionable
MDWD MediWound	121	12.85 million	11.67 million	Optionable
NGNE Neurogene	131	20.01 million	17.67 million	Optionable
SGMT Sagimet Biosciences	16	62.16 million	55.01 million	Optionable

MDWD, SGMT, AURA, and NGNE Headlines

Recent News About These Companies

Sagimet Biosciences (SGMT): Phase 3 Trial, FDA Path and Cash Runway Set Up Key Catalysts

September 27 at 11:47 PM | finance.yahoo.com

Sagimet Biosciences (NASDAQ:SGMT) Research Coverage Started at The Goldman Sachs Group

September 27 at 1:48 AM | americanbankingnews.com

The Goldman Sachs Group Upgrades Sagimet Biosciences (NASDAQ:SGMT) to Strong Sell

September 25 at 8:05 AM | marketbeat.com

Sagimet Biosciences Inc. (NASDAQ:SGMT) Stock Has Consensus Target Price of $25.34 According to Analysts

September 25 at 2:15 AM | americanbankingnews.com

Sagimet Biosciences Inc. (NASDAQ:SGMT) Stock Has Consensus Price Target of $25.34

September 25 at 2:13 AM | marketbeat.com

Sagimet Biosciences (NASDAQ:SGMT) Shares Gap Down - What's Next?

September 24, 2026 | marketbeat.com

Cours Sagimet Biosciences Inc.

September 23, 2026 | zonebourse.comZ

Sagimet Biosciences (NASDAQ:SGMT) Stock Price Up 4.1% - Time to Buy?

September 10, 2026 | marketbeat.com

Sagimet Biosciences (NASDAQ:SGMT) Upgraded at Cantor Fitzgerald

September 10, 2026 | marketbeat.com

Bank of New York Mellon Corp Invests $1.55 Million in Sagimet Biosciences Inc. $SGMT

September 10, 2026 | marketbeat.com

Cantor Fitzgerald initiates coverage of Sagimet Biosciences at overweight

September 9, 2026 | msn.com

Barclays upgrades Sagimet Biosciences to overweight from equal-weight

September 9, 2026 | msn.com

Sagimet Biosciences (NASDAQ:SGMT) Hits New 52-Week High - Here's Why

September 9, 2026 | marketbeat.com

Seven Fleet Capital Management LP Buys Shares of 403,545 Sagimet Biosciences Inc. $SGMT

September 5, 2026 | marketbeat.com

Sagimet Biosciences (NASDAQ:SGMT) Sets New 1-Year High - Should You Buy?

September 3, 2026 | marketbeat.com

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Average Rating of "Moderate Buy" from Analysts

August 31, 2026 | marketbeat.com

Sagimet Biosciences Announces AURORA Phase 3 Acne Trial on Track to Begin Enrollment in Q4 2026

August 25, 2026 | quiverquant.comQ

Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026

August 25, 2026 | globenewswire.com

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 17, 2026 | markets.businessinsider.com

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 17, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MDWD, SGMT, AURA, and NGNE Company Descriptions

Aura Biosciences NASDAQ:AURA

$6.00 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$6.00 +0.00 (+0.08%)

As of 09/25/2026 07:30 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

MediWound NASDAQ:MDWD

$13.84 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$13.88 +0.04 (+0.33%)

As of 09/25/2026 07:30 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Neurogene NASDAQ:NGNE

$28.31 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$28.48 +0.17 (+0.60%)

As of 09/25/2026 07:49 PM Eastern

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Sagimet Biosciences NASDAQ:SGMT

$9.24 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$9.20 -0.04 (-0.38%)

As of 09/25/2026 07:59 PM Eastern

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDWD, SGMT, AURA, and NGNE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDWD, SGMT, AURA, and NGNE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDWD, SGMT, AURA, and NGNE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MDWD, SGMT, AURA, and NGNE Company Descriptions

Aura Biosciences NASDAQ:AURA

MediWound NASDAQ:MDWD

Neurogene NASDAQ:NGNE

Sagimet Biosciences NASDAQ:SGMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDWD, SGMT, AURA, and NGNE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDWD, SGMT, AURA, and NGNE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDWD, SGMT, AURA, and NGNE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MDWD, SGMT, AURA, and NGNE Company Descriptions

Aura Biosciences NASDAQ:AURA

MediWound NASDAQ:MDWD

Neurogene NASDAQ:NGNE

Sagimet Biosciences NASDAQ:SGMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools